by Andreu Prados
A new randomized, placebo-controlled, double-blind study has found both clinical and mechanistic evidence that metformin’s improved blood glucose control is achieved through modulation of the gut microbiota.
The main researchers behind those successful and ambitious projects attended the Gut Microbiota for Health World Summit held in Paris, in March 2017, where we could interview them.
by GMFH Editing Team
Recent research has shed light on the importance of gut microbiota both during pregnancy and early life. Despite recent research that shows the placenta is not sterile, as previously thought, gut microbiota colonization in the first days and weeks after birth appears to have enormous significance for post-natal life.
by Andreu Prados
In a recent study, led by Dr. Matteo Serino from the Institut Nacional de la Santé et de la Recherche Médicale (INASERM) in Toulouse (France), has found that transfer of a dysbiotic microbiota had the capacity to induce metabolic effects that appear beneficial.
by Paul Enck
A recent study, led by Dr. Paul Wilmes from the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg (Luxembourg), adds new insights about the human microbiome in type 1 diabetes mellitus (T1DM) from an integrated multi-omics analysis.
by Kristina Campbell
Previous studies have identified Akkermansia muciniphila as an important bacterium in metabolic health—able to prevent the development of obesity in animal models. Until now, however, its mechanisms were unclear and its effects had never been tested in humans.
by Andreu Prados
A recent study, led by Dr. Oluf Pedersen from the Faculty of Health and Medical Sciences at University of Copenhagen in Denmark, has found that dysbiosis of the human gut microbiota impacts the serum metabolome and contributes to the state of IR and metabolic syndrome.
by Andreu Prados
It has been previously reported that the gut microbiota could be involved in the pathogenesis of metabolic diseases such as diabetes. A recent study, led by Dr. Wolfgang zu Castell from the Scientific Computing Research Unit at Helmholtz Zentrum München in Munich (Germany) has found that butyrate may have a protective effect in the pathogenesis of type 1 diabetes.
Gestational diabetes mellitus (GDM) is one of the most frequent metabolic complications of pregnancy and its prevalence is up to 12% in developed countries. Nowadays, several studies are investigating new therapies for glucose control that may complement diet, exercise, and pharmacological therapies.
The prevalence of type 2 diabetes (T2D) is increasingly rapidly around the globe and has challenged researchers to investigate the underlying pathophysiological mechanisms.
